Date of Report (Date of earliest event reported): January 8, 2019 |
GENMARK DIAGNOSTICS, INC. |
(Exact name of registrant as specified in its charter) Commission File Number: 001-34753 |
Delaware | 27-2053069 | |
(State or other jurisdiction of incorporation) | (I.R.S. Employer Identification No.) |
5964 La Place Court Carlsbad, California 92008 |
(Address of principal executive offices, including zip code) |
760-448-4300 |
(Registrant’s telephone number, including area code) |
(Former Name or Former Address, if Changed Since Last Report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): |
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2). |
Emerging Growth Company o |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Selection 13(a) of the Exchange Act. o |
(d) | The following exhibit is furnished with this Current Report: |
99.1 | Press release dated January 8, 2019 |
GENMARK DIAGNOSTICS, INC. | ||
Date: | January 8, 2019 | /s/ Scott Mendel |
Scott Mendel | ||
Chief Financial Officer | ||
Exhibit Number | Description | |
• | Total revenue for 2018 expected to be approximately $70.8 million, representing an increase of 35% over 2017 |
◦ | ePlex® revenue for the full year 2018 expected to be approximately $37.9 million, an increase of more than 270% over 2017 |
• | Total revenue for the fourth quarter of 2018 expected to be approximately $19.4 million, representing an increase of 21% over the fourth quarter of 2017 |
◦ | ePlex revenue for the fourth quarter of 2018 expected to be approximately $12.1 million, an increase of approximately 110% versus the fourth quarter of 2017 |
• | Cash and investments at December 31, 2018 of approximately $45.2 million |
• | Placed 42 ePlex analyzers in the fourth quarter of 2018, finishing the year with an installed base of 354 ePlex analyzers in U.S. and European labs |
• | Received FDA 510(k) Market Clearance for the company’s ePlex Blood Culture Identification Gram-Positive Panel (BCID-GP) and Fungal Pathogen Panel (BCID-FP) |